mecanismos vaso activos ii · 2018-06-07 · •alpha-adrenoceptor antagonistas (alpha-blockers)...
TRANSCRIPT
![Page 1: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/1.jpg)
Mecanismos Vaso activos IIProf. Dr. Mag. Rafael Porcile
D E P A R T A M E N T O D E C A R D I O L O G I A
C A T E D R A D E F I S I O L O G Í A
Universidad Abierta Interamericana
![Page 7: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/7.jpg)
•Alpha-adrenoceptor antagonistas (alpha-blockers)
•Angiotensina converting enzyme (ACE) inhibitors
•Angiotensin receptor blockers (ARBs)
•Beta2-adrenoceptor agonists (β2-agonists)
•Calcium-channel blockers (CCBs)
•Centrally acting sympatholytics
•Direct acting vasodilators
•Endothelin receptor antagonists
•Ganglionic blockers
•Nitrodilators
•Phosphodiesterase inhibitors
•Potassium-channel openers
•Renin inhibitors
![Page 8: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/8.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 9: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/9.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 12: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/12.jpg)
Cuatro tipos de
vasodilatadores • GMP c o AMP c dependientes
• Inhibidores ALFA
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 13: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/13.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
![Page 14: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/14.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
![Page 15: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/15.jpg)
Cuatro tipos de
vasodilatadores • GMP c o AMP c dependientes
• Inhibidores ALFA
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 16: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/16.jpg)
Cuatro tipos de
vasodilatadores • GMP c o AMP c dependientes
• Inhibidores ALFA
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 18: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/18.jpg)
Fosforilación
Catalítica cadena
liviana miosinaPGE2
Epoprostenol
Selexipag
AMP c2
Histamina
Adenosina
![Page 19: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/19.jpg)
Fosforilación
Catalítica cadena
liviana miosinaPGE2
Epoprostenol
Selexipag
AMP c2
Histamina
Adenosina
![Page 20: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/20.jpg)
![Page 21: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/21.jpg)
![Page 22: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/22.jpg)
Fosforilación
Catalítica cadena
liviana miosinaPGE2
Epoprostenol
Selexipag
AMP c2
Histamina
Adenosina
![Page 23: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/23.jpg)
Fosforilación
Catalítica cadena
liviana miosinaPGE2
Epoprostenol
Selexipag
AMP c2
Histamina
Adenosina
![Page 25: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/25.jpg)
Epoprostenol (Flolan)
WHO Class III / IV
Intravenosa vía central venouscatheter
Half life approx 4
Minutes
DISPONIBILIDAD
EN ARGENTINA
![Page 27: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/27.jpg)
Meta-Analysis of Published Randomized Controlled
With Epoprostenol in Pulmonary Arterial Hypertension
by Mantel–Haenszel and Peto Methods
The analysis included 215 patients in 3 trials.
![Page 31: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/31.jpg)
Selexipag
Selexipag is a prostacyclin IP receptor
agonist. It is not prostacyclin or a
prostacyclin analog. It is orally available
and undergoes rapid hydrolysis to the
active metabolite, ACT-333679
![Page 33: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/33.jpg)
Selexipag
Selective prostacyclin IP receptor agonist
The GRIPHON study
Designed to demonstrate a
prolongation of time to the first
morbidity/mortality event for
selexipag compared to placebo and
to evaluate the safety of the
selexipag in PAH patients.
![Page 34: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/34.jpg)
Selexipag
Selective prostacyclin IP receptor agonist
The GRIPHON study
.
Selexipag decreased the risk of a
morbidity/mortality event versus placebo
by 39% (p<0.0001).Functional Class, PAH etiology and background PAH therapy.
Patients were treated for up to 4.3 years. The overall tolerability
profile of selexipag in GRIPHON was consistent with
prostacyclin therapies
![Page 35: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/35.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
![Page 36: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/36.jpg)
Tres tipos de vasodilatadores
• GMP c o AMP c dependientes
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la [email protected]
![Page 37: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/37.jpg)
[email protected]@uaisalud.com.ar
![Page 38: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/38.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 39: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/39.jpg)
Calcio
GMPc
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 41: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/41.jpg)
Guamilato
ciclasa
fosforilada
En la membrana
Guamilato
ciclasa soluble
En el citoplasma
[email protected]@uaisalud.com.ar
![Page 43: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/43.jpg)
![Page 46: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/46.jpg)
![Page 47: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/47.jpg)
GMPcEstimula
Guamilato
ciclasa
soluble
En el
citoplasma
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Donantes de
oxido nítrico
Relaxina
Vericiguat
Riociguat
![Page 49: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/49.jpg)
GMPcEstimula
Guamilato
ciclasa
soluble
En el
citoplasma
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Donantes de
oxido nítrico
Riociguat
Relaxina
Ulatitide
Vericiguat
![Page 50: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/50.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 51: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/51.jpg)
Calcio
GMPc
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 52: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/52.jpg)
Calcio
GMPc
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 53: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/53.jpg)
Oxido nirtico
![Page 54: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/54.jpg)
![Page 55: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/55.jpg)
![Page 58: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/58.jpg)
Guamilato
ciclasa
Posforilada
Reduce la concentración de
Calcio citoplasmática
Guamilato
ciclasa soluble
En el citoplasma
![Page 59: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/59.jpg)
![Page 60: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/60.jpg)
![Page 61: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/61.jpg)
![Page 62: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/62.jpg)
Cinco minutos
![Page 63: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/63.jpg)
GMPcEstimula
Guamilato
ciclasa
soluble
En el
citoplasma
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Donantes de oxido
nítrico
Riociguat
Ulatitide
Relaxina
Vericiguat
![Page 64: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/64.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 65: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/65.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 66: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/66.jpg)
RIOCIGUAT
Dosificación.
Por vía oral 1mg, 3 veces por día
durante 2 semanas. Dosis diaria
máxima 7,5mg (25mg 3 veces por
día).
![Page 68: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/68.jpg)
Left Ventricular Systolic
Dysfunction Associated With
Pulmonary Hypertension
Riociguat Trial
201 pacientes con insuficiencia cardiaca
causada por HAP secundaria a disfunción
sistólica ventricular izquierda.
A Phase IIb Double-Blind, Randomized, Placebo-
Controlled, Dose-Ranging Hemodynamic Study
Bonderman D et al. Circulation. 2013;128:502-511
![Page 70: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/70.jpg)
Left Ventricular Systolic
Dysfunction Associated With
Pulmonary Hypertension
Riociguat Trial
Aumentaron el índice cardiaco (0.4 Lキmin−1キm−2; p= 0.0001) y el índice de volumen
de eyección (5.2 mlキm−2; p= 0.0018) sin que
se observaran cambios en la frecuencia
cardiaca ni la presión sistólica sistémica.
![Page 71: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/71.jpg)
Left Ventricular Systolic
Dysfunction Associated With
Pulmonary Hypertension
Riociguat Trial
Asimismo se registró una mejoría de la
calidad de vida asociada al tratamiento con
riociguat reflejada en una disminución de la
puntuación del Minnesota Living With Heart
Failure Score (p= 0.0002)
![Page 72: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/72.jpg)
Asimismo se registró una mejoría de la calidad de vida asociada al
tratamiento con riociguat reflejada en una disminución de la puntuación del
Minnesota Living With Heart Failure Score (p= 0.0002)
Bonderman D et al. Circulation. 2013;128:502-511 Copyright © American Heart Association, Inc. All rights reserved.
¿Mortalidad?
![Page 75: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/75.jpg)
GMPcEstimula
Guamilato
ciclasa
soluble
En el
citoplasma
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Vericiguat
Relaxina
Ulatitide
![Page 77: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/77.jpg)
![Page 78: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/78.jpg)
Primary analysis:
NT-proBNPreduction in pooled 2.5/5/10 mg dose groups >
reduction in placebo (NS, [email protected]
![Page 79: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/79.jpg)
El análisis final en el grupo de
mayor dosis se asoció a menor
numero de eventos y mejoría de
la fracción de eyección a 12 meses
![Page 82: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/82.jpg)
Conclusion: Vericiguat was well tolerated, did not change
NT-proBNP and LAV at 12 weeks compared with placebo
but was associated with improvements in quality of life in
patients with HFpEF. Given the encouraging results on
quality of life, the effects of vericiguat in patients with
HFpEF warrant further study, possibly with higher doses,
longer follow-up and additional endpoints. Vericiguat in
patients with worsening
Vericiguat in patients with worsening chronic heart failure
and preserved ejection fraction: results of the SOluble
guanylate Cyclase stimulatoR in heArT failurE patientS with
PRESERVED EF (SOCRATES-PRESERVED) study
European Heart Journal 38(15) · March 2017
![Page 84: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/84.jpg)
Calcio
GMPc
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 85: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/85.jpg)
Calcio
GMPc
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 87: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/87.jpg)
• AUMENTO DEL 20 %
VM CARDÍACO A
PARTIR DEL PRIMER
TRIMESTRE
• Caida del 30 %
RESISTENCIAS
VASCULARES
SISTEMICAS
• AUMENTO DE LA
COMPLIANCE
VASCULAR ARTERIAL
30 %
• AUMENTO DEL FLUJO
PLASMATICO RELAN
45 %
Se producen en el cuerpo lúteo
del ovario, la mama y, durante
el embarazo, también en la
placenta, corion, y decidua.
![Page 95: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/95.jpg)
GMPcEstimula
Guamilato
ciclasa
soluble
En el
citoplasma
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Vericiguat
Relaxina
Ulatitide
![Page 96: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/96.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 97: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/97.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 98: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/98.jpg)
Ulatitide
![Page 99: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/99.jpg)
![Page 100: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/100.jpg)
![Page 101: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/101.jpg)
![Page 102: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/102.jpg)
![Page 103: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/103.jpg)
![Page 104: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/104.jpg)
Cinco minutos
![Page 105: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/105.jpg)
GMPcEstimula
Guamilato
ciclasa soluble
En el citoplasma
Estimular
Guamilato
ciclasa
fosforilada
En la membrana
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Inhibir su degradación por la fosfodiesterasa
![Page 106: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/106.jpg)
GMPcEstimular
Guamilato
ciclasa
fosforilada
En la
membrana
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO [email protected]
![Page 107: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/107.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 108: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/108.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 111: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/111.jpg)
Los péptidos natriuréticos son eliminados por el NPR-C y la
neprilisina
ANP: péptido natriurético auricular; Ang: angiotensina; AT1: angiotensina II tipo 1; BNP: péptido natriurético tipo B; cGMP: monofosfato de guanosina cíclico;
CNP: péptido natriurético tipo C; GTP: trifosfato de guanosina; IC: insuficiencia cardíaca; PN: péptido natriurético; RPN: receptor del péptido natriurético; SRAA: sistema renina-angiotensina-aldosterona
Levin et al. N Engl J Med 1998;339;321–8; Gardner et al. Hypertension 2007;49:419–26; Molkentin. J Clin Invest 2003;111:1275–77; Nishikimi et al. Cardiovasc Res 2006;69:318–28; Guo et al. Cell Res
2001;11:165–80; Von Lueder et al. Circ Heart Fail 2013;6:594–605; Yin et al. Int J Biochem Cell 2003;35:780–3; Mehta & Griendling. Am J Physiol Cell Physiol 2007;292:C82–97
GTPGTP
cGMPPéptidos inactivos
ANP/CNPANP BNP
NPR-A
Internalización
Neprilisina
Vasodilación
fibrosis/hipertrofia cardíacas
natriuresis/diuresis
Señalización y
efectos de los
PNDegradación y
depuración de los
PN
La neprilisinaes una
endopeptidasa
que degrada
múltiples
péptidos
endógenos vaso
activos, glucagon,
neurotensina,
oxitocina, y
bradikinina
![Page 112: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/112.jpg)
Original Article
Angiotensin–Neprilysin Inhibition versus Enalapril in
Heart Failure
John J.V. McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., Michael R. Zile, M.D., for the PARADIGM-HF Investigators and Committees
N Engl J MedVolume 371(11):993-1004
September 11, 2014
![Page 114: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/114.jpg)
La inhibición conjunta del sistema
renina – angiotensina y neprilisina
ha sido superior que la inhibición
de sólo uno de ellos.
Sin embargo en ensayos clínicos la
inhibición conjunta de la enzima
convertidora de angiotensina y
neprilisina se asoció a angioedema.
![Page 115: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/115.jpg)
ANP: péptido natriurético auricular; Ang: angiotensina; AT1: angiotensina II tipo 1; BNP: péptido natriurético tipo B; cGMP: monofosfato de guanosina cíclico;
CNP: péptido natriurético tipo C; GTP: trifosfato de guanosina; PN: péptido natriurético; RPN: receptor del péptido natriurético; SRAA: sistema renina-angiotensina-aldosterona
Levin et al. N Engl J Med 1998;339;321–8; Gardner et al. Hypertension 2007;49:419–26; Molkentin. J Clin Invest 2003;111:1275–77; Nishikimi et al. Cardiovasc Res 2006;69:318–28; Guo et
al. Cell Res 2001;11:165–80; Von Lueder et al. Circ Heart Fail 2013;6:594–605; Yin et al. Int J Biochem Cell 2003;35:780–3; Mehta & Griendling. Am J Physiol Cell Physiol 2007;292:C82–97;
Langenickel & Dole. Drug Discovery Today: Ther Strateg 2012;9:e131–9
Cascadas
de señalización
GTP GTP
cGMP
Péptidos inactivos
ANP/CNPANP BNP
NPR-A
CNP
NPR-B
Fragmentos de
PN inactivosANP/CNP/BNP
NPR-C
Ang II
receptor AT1
Internalización
Reciclado
del receptor
Neprilisina
Vasodilación
fibrosis/hipertrofia cardíacas
natriuresis/diuresis
Vasoconstricción
fibrosis/hipertrofia cardíacas
retención de sodio/agua
Sacubitrilo/valsartan
Sacubitrilo
Potenciación del sistema de
péptidos natriuréticos Supresióndel SRAA
Valsartán
El Sacubitrilo/valsartán potencia simultáneamente los efectos beneficiosos del
sistema de PN al tiempo que bloquea los efectos perjudiciales del SRAA
Vasoconstricción
fibrosis/hipertrofia cardíacas
retención de sodio/agua
![Page 116: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/116.jpg)
Screening Criteria,.
McMurray JJ et al. N Engl J Med 2014;371:993-1004.
Se incluyeron 10513pacientes en clase funcional II,
III o IV, con fracción de eyección
igual o menor al 40%.
Se randomizaron 8442a dos
ramas:
*Enalapril (10 mg cada 12
horas) *LCZ696 (200 mg c/12
hs).
ADD ON
Antagonistas de aldosterona
(54%), beta bloqueantes (93%),
y digitales (29%).
![Page 117: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/117.jpg)
Según estos resultados, se necesitarán
tratar (NNT) a 35 personas para evitar
una muerte
![Page 118: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/118.jpg)
2016 ESC Guidelines for the
diagnosis and treatment of acute
and chronic heart failure
DOI: http://dx.doi.org/10.1093/eurheartj/ehw1282129-
2200 First published online: 20 May 2016
![Page 119: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/119.jpg)
Therapeutic algorithm for a patient with symptomatic heart failure with reduced ejection fraction.
Piotr Ponikowski et al. Eur Heart J 2016;37:2129-2200
![Page 121: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/121.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
• Pacientes con tratamiento sub óptico
Antagonistas de aldosterona (54%),
EMPHASIS-HF6
(2014)2.737 pacientes Beneficios clave de la eplerenona
(ARM) vs. placebo:
•37% mortalidad por causa CV u
hospitalización por IC
![Page 122: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/122.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
• En el período de Run In Prueba 2071 pacientes
quedaron afuera por intolerancia El 20% .
Incluyeron solo a los tolerantes sin utilizar ITT
![Page 123: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/123.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
• ¿Los resultados son extrapolables a
pacientes con icc estadio A y B o C en
clase funcional I?
![Page 124: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/124.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
¿Como afecta la droga el uso del
pro bnp como medio diagnostico
y de monitoreo?
![Page 125: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/125.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
¿Aumenta el riesgo de
alzhéimer? El B amiloide es
lisado por la neprilisina
![Page 126: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/126.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
La insuficiencia cardíaca es un
trastorno que afecta a los ancianos,
pero en el PARADIGMA-HF la edad
promedio fue de 64 años de edad,
bastante menor que el típico
paciente con insuficiencia cardíaca.
![Page 127: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/127.jpg)
CUESTIONES PENDIENTE
LUEGO DEL ESTUDIO
La dosis de valsartán (del LCZ696) fue de
200 mg dos veces al día, es decir, la dosis
máxima del valsartán. Mientras que el
enalapril (del grupo control) se dosificó
con 10 mg dos veces al día, inferior a la
dosis máxima es de 40 mg al día
![Page 128: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/128.jpg)
![Page 129: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/129.jpg)
GMPcEstimula
Guamilato
ciclasa soluble
En el citoplasma
Estimular
Guamilato
ciclasa
fosforilada
En la membrana
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Inhibir su degradación por la fosfodiesterasa
![Page 130: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/130.jpg)
GMPc
SOLO TRES LLAVES HACIA LA ESTIMULACÍON
DEL GMP CICLICO
Inhibir su degradación por la
fosfodiesterasa
![Page 131: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/131.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 132: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/132.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
GMPc
AMP c
Fosfodiesterasa
Oxido Nítrico
BNP
Sildenafil
Cilostazol
Sarcubitrilo
Nitroglicerina
Nitro prusiato de Sodio
Di nitrato de isosorbide
Riociguat
Serelaxina
Ularitide
![Page 135: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/135.jpg)
Sildenafil Improves Exercise Capacity and Quality of Life in
Patients With Systolic Heart Failure and Secondary Pulmonary
Hypertension
Gregory D. Lewis, Ravi Shah, Khurram Shahzad, Janice M.
Camuso,
Circulation. 2007;116:1555-1562
Phosphodiesterase 5 inhibition with sildenafil improves exercise
capacity and quality of life in patients with systolic HF with
secondary PH.
![Page 136: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/136.jpg)
Gregory D. Lewis et al. Circulation. 2007;116:1555-1562
Copyright © American Heart Association, Inc. All rights reserved.
Phosphodiesterase 5 inhibition with sildenafil improves
exercise capacity and quality of life in patients with
systolic HF with secondary PH.
![Page 137: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/137.jpg)
CILOSTAZOL
![Page 138: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/138.jpg)
![Page 139: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/139.jpg)
![Page 140: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/140.jpg)
Cuatro tipos de
vasodilatadores • GMP c o AMP c dependientes
• Inhibidores ALFA
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 141: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/141.jpg)
Cuatro tipos de
vasodilatadores • GMP c o AMP c dependientes
• Inhibidores ALFA
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 142: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/142.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 143: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/143.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
![Page 144: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/144.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Bloqueador Uso
Nombre
comercial
común
Doxazosin
Hipertensión
e hiperplasia
benigna de
próstata
(HBP)
(Cardura)
Silodosin
Hiperplasia
benigna de
próstata
(Rapaflo)
Prazosin Hipertensión (Minipress)
Tamsulosina
Benign
prostatic
hyperplasia
(Flomax)
Alfuzosina
Benign
prostatic
hyperplasia
(Uroxatral)
![Page 145: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/145.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
![Page 146: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/146.jpg)
![Page 147: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/147.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
![Page 148: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/148.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
![Page 149: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/149.jpg)
![Page 150: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/150.jpg)
Efecto
alfabloquenate
de los
betabloqueantes
![Page 151: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/151.jpg)
Efectos vasodilatadores de
los betabloqueantes
![Page 152: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/152.jpg)
Efectos vasodilatadores de los
betabloqueantes
![Page 153: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/153.jpg)
Tres tipos de vasodilatadores
• GMP c o AMP c dependientes
• Inhibidores directos del Ca
citoplasmático
• Inhibidores directos dela Fosforilacíon
cadena liviana de la miosina
![Page 154: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/154.jpg)
Calcio
Fosforilación
Catalítica cadena
liviana miosina
Pg1/Prostaciclinas
Endotelina
E1
GMPc
AMP c
Fosfodiesterasa
2
Oxido Nítrico
BNP
Vasopresina
HistaminaAngiotensina II
IP3
RhoKinasa
Angiotensina II
Tromboxano A2
![Page 155: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/155.jpg)
Calcio
![Page 156: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/156.jpg)
Calcio
![Page 157: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/157.jpg)
Calcio
![Page 158: Mecanismos Vaso activos II · 2018-06-07 · •Alpha-adrenoceptor antagonistas (alpha-blockers) •Angiotensina converting enzyme (ACE) inhibitors •Angiotensin receptor blockers](https://reader033.vdocumento.com/reader033/viewer/2022042803/5f48c523a0f8cc35686873ec/html5/thumbnails/158.jpg)
Calcio